公开(公告)号：US20210179607A1

公开(公告)日：2021-06-17

申请号：US16758717

申请日：2018-10-29

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yongqi Deng ,  Abdelghani Achab ,  Bridget A. Becker ,  David Jonathan Bennett ,  Indu Bharathan ,  Xavier Fradera ,  Craig Gibeau ,  Yongxin Han ,  Derun Li ,  Kun Liu ,  Qinglin Pu ,  Sulagna Sanyal ,  David Sloman ,  Wensheng Yu ,  Hongjun Zhang

IPC: C07D471/04 ,  C07D215/14 ,  A61K45/06

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20210161896A1

公开(公告)日：2021-06-03

申请号：US17267866

申请日：2019-08-12

Applicant: Merck Sharp & Dohme Corp.

Inventor： Dane Clausen ,  Xavier Fradera ,  Yongxin Han ,  Alexander Pasternak ,  Li Xiao ,  Hongjun Zhang

IPC: A61K31/506 ,  A61K45/06 ,  C07D215/20 ,  C07D401/12 ,  C07D401/04 ,  A61K31/47 ,  A61K31/4709

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US10927086B2

公开(公告)日：2021-02-23

申请号：US16483957

申请日：2018-02-19

Applicant: Merck Sharp & Dohme Corp. ,  Kun Liu ,  Dane Clausen ,  Liangqin Guo ,  Yongxin Han ,  Shuwen He ,  Joseph Kozlowski ,  Derun Li ,  Qinglin Pu ,  Wensheng Yu ,  Hongjun Zhang

Inventor： Kun Liu ,  Dane Clausen ,  Liangqin Guo ,  Yongxin Han ,  Shuwen He ,  Joseph Kozlowski ,  Derun Li ,  Qinglin Pu ,  Wensheng Yu ,  Hongjun Zhang

IPC: C07D271/08 ,  C07D413/12

Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US10344000B2

公开(公告)日：2019-07-09

申请号：US15770255

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe ,  Peter H. Fuller ,  Hakan Gunaydin ,  Kun Liu ,  Danielle F. Molinari ,  Qinglin Pu ,  Mark E. Scott ,  B. Wesley Trotter ,  Hongjun Zhang

IPC: C07D231/56 ,  C07D401/04 ,  C07D491/052 ,  C07D491/107 ,  A61P19/02 ,  A61P17/06 ,  A61P29/00 ,  A61P37/02 ,  A61P11/06 ,  C07D471/04

Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US20190194186A1

公开(公告)日：2019-06-27

申请号：US15770257

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Hongjun Zhang ,  Kenneth Jay Barr ,  Blair T. Lapointe ,  Hakan Gunaydin ,  Kun Liu ,  B. Wesley Trotter

IPC: C07D471/04 ,  A61P37/00 ,  A61P29/00 ,  A61P19/02 ,  A61P11/06

CPC classification number: C07D471/04 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00 ,  A61P37/00

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US10287272B2

公开(公告)日：2019-05-14

申请号：US15770256

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe ,  Peter H. Fuller ,  Hakan Gunaydin ,  Kun Liu ,  Mark E. Scott ,  B. Wesley Trotter ,  Hongjun Zhang

IPC: C07D403/08 ,  C07D403/12 ,  C07D231/56 ,  C07D403/06 ,  C07D403/14 ,  C07D405/12 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D491/048 ,  C07D401/06 ,  C07D401/12 ,  A61P19/02 ,  A61K31/416

Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment o RORgammaT-mediated diseases or conditions.

公开(公告)号：US20180362482A1

公开(公告)日：2018-12-20

申请号：US16061597

申请日：2016-12-12

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yongxin Han ,  Abdelghani Achab ,  Purakkattle Biju ,  Yongqi Deng ,  Xavier Fradera ,  Liangqin Guo ,  Shuwen He ,  Joseph Kozlowski ,  Ravi Kurukulasuriya ,  Kun Liu ,  Meredeth Ann McGowan ,  Qinglin Pu ,  Nunzio Sciammetta ,  Hongjun Zhang ,  Hua Zhou

IPC: C07D271/08 ,  C07D285/10 ,  C07D413/12 ,  A61P25/24 ,  A61P25/28 ,  A61P35/02 ,  A61P31/14 ,  A61P27/12 ,  A61P37/06

CPC classification number: C07D271/08 ,  A61P25/24 ,  A61P25/28 ,  A61P27/12 ,  A61P31/14 ,  A61P35/02 ,  A61P37/06 ,  C07D285/10 ,  C07D413/12 ,  C07D417/12 ,  C07F9/65318

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20180022701A1

公开(公告)日：2018-01-25

申请号：US15647437

申请日：2017-07-12

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Kenneth J. Barr ,  Corey E. Bienstock ,  John K. Maclean ,  Hongjun Zhang ,  Richard T. Beresis ,  Dongshan Zhang ,  Neville J. Anthony ,  Blair T. Lapointe ,  Yuan Tian

IPC: C07D209/26 ,  C07D471/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  A61K31/404 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/416 ,  C07D405/12 ,  C07D231/56

CPC classification number: C07D209/26 ,  A61K31/404 ,  A61K31/416 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04 ,  C07D471/04 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US20180016239A1

公开(公告)日：2018-01-18

申请号：US15549465

申请日：2016-02-11

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe ,  Peter H. Fuller ,  Hakan Gunaydin ,  Kun Liu ,  Nunzio Sciammetta ,  Benjamin Wesley Trotter ,  Hongjun Zhang ,  Kenneth J. Barr ,  John K. F. Maclean ,  Danielle F. Molinari ,  Vladimir Simov

IPC: C07D231/56 ,  A61K31/416 ,  A61K45/06 ,  C07D487/04

CPC classification number: C07D231/56 ,  A61K31/416 ,  A61K45/06 ,  A61K2300/00 ,  C07D403/12 ,  C07D405/12 ,  C07D413/06 ,  C07D471/04 ,  C07D487/04 ,  C07D487/06 ,  C07D487/14 ,  C07D491/052 ,  C07D491/107 ,  C07D495/04 ,  C07D513/04 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US20170340610A1

公开(公告)日：2017-11-30

申请号：US15463371

申请日：2017-03-20

Applicant: Merck Sharp & Dohme Corp. ,  Merck Sharp & Dohme B.V.

Inventor： Willem Frederik Johan Karstens ,  Mario Van Der Stelt ,  Jos Cals ,  Rita Corte Real Goncalves ,  Kenneth Jay Barr ,  Hongjun Zhang ,  Richard Thomas Beresis ,  Dongshan Zhang ,  Xiaobang Duan

IPC: A61K31/416 ,  C07D413/14 ,  C07D413/12 ,  C07D409/14 ,  C07D403/10 ,  C07D401/12 ,  A61K31/422 ,  C07D231/56 ,  A61K45/06 ,  A61K31/4709 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/4245 ,  C07D401/06 ,  C07D471/04

CPC classification number: A61K31/416 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K45/06 ,  C07D231/56 ,  C07D401/06 ,  C07D401/12 ,  C07D403/10 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.